VivoSeq
Oncology

Muscle-Invasive Bladder Carcinoma

5

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Muscle-Invasive Bladder Carcinoma is an early-stage landscape with 5 programs across 4 companies. The most active players are Celldex Therapeutics, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Celldex Therapeutics

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

1 program

PreclinicalU

UroGen Pharma Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSVaccine117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Recruiting·WWashington University School of Medicine·Phase 1·NCT06529822·64 enrolled
Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Phase I/II Pilot Feasibility Trial
Not yet recruiting·UUniversity of Washington·Preclinical·NCT07579195·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)